Introduction
============

Interleukin-18 (IL-18) is a pro-inflammatory cytokine which has been linked with varying degrees of evidence to diseases as diverse as cardiovascular disease ([@ref-33]), asthma ([@ref-42]), inflammatory bowel disease ([@ref-52]; [@ref-43]; [@ref-48]), acute kidney injury ([@ref-30]), and type 1 ([@ref-55]) and type 2 diabetes ([@ref-59]; [@ref-29]), either through associations with IL-18 itself or with its receptor or binding protein. The IL-18 receptor belongs to the interleukin-1/Toll-like receptor superfamily, and is encoded by two genes---*IL18R1* and *IL18RAP*---which encode a ligand-binding subunit (commonly known as IL-18R*α*) and accessory protein (IL-18R*β*) subunit, respectively ([@ref-19]). The ligand-binding subunit, IL-18R*α*, is also capable of binding a related cytokine, IL-37b (also known as IL-1F7b), to exert anti-inflammatory effects ([@ref-10]).

A mouse cDNA library generated by the Mammalian Gene Collection Program ([@ref-58]) was later found by [@ref-2] to include a cDNA sequence corresponding to a splice variant of *IL18r1*, formed by inclusion of part of an unspliced intron in the mRNA sequence. [@ref-2] named this variant type II *IL18r1*, with the reference sequence inheriting the nomenclature type I *IL18r1*, and presented evidence for its expression in the mouse brain. The reading frame resulting from inclusion of an unspliced intron introduces a stop codon shortly into the unspliced intron sequence. This splice variant would therefore be expected to translate into a truncated receptor with intact extracellular and transmembrane domains, but also a short cytoplasmic domain lacking the toll/interleukin-1 receptor (TIR) domain characteristic of IL-1 receptor family members. Given evidence suggestive of a role for IL-18 in the pathogenesis of a range of diseases in humans, we experimentally investigated whether a similar splice variant could exist in humans, finding evidence for an equivalent human type II *IL18R1* transcript. Similar results were obtained in the rat, another commonly used laboratory rodent. IL-18 and its receptor are evolutionarily conserved across a wide range of species, and we therefore assessed whether transcription of homologous intron sequences in other species would be expected to generate truncated IL-18R*α* subunits by assessing the predicted coding sequences of putative type II *IL18R1* transcripts across a range of species with available *IL18R1* gene records. These analyses suggest that the generation of truncated IL-18R*α* subunits through alternative splicing may form a widespread mechanism of regulating IL-18 activity.

Materials and Methods
=====================

Ethics statement
----------------

All experimental procedures were approved by institutional ethics committees. The Animal Ethics Committee of the University of Otago, Dunedin, New Zealand, approved experiments involving rats (project number 58/07). For experimental procedures involving human samples, the only subject was the corresponding author (CB) and the research describes experimental work conducted on samples collected from the author. No written consent was obtained. This research was approved by the Human Ethics Committee of the University of Otago, Dunedin, New Zealand (project number 11/153).

Bioinformatics searches for prior evidence of human type II IL18R*α*
--------------------------------------------------------------------

In order to investigate whether an mRNA sequence incorporating intron 8-9 of the human *IL18R1* reference sequence (Ensembl accession number: [ENST00000233957](ENST00000233957), [NM_003855.2](NM_003855.2)) had been previously observed, BLAST searches were performed for cDNA or expressed sequence tags showing similarity to a 362 nt portion of the expected nucleotide sequence, covering the first 60 nucleotides of intron 8-9 preceded by the coding sequences of the two upstream exons (GACTCCAGAAGGCAAATGGCATGCTTCAAAAGTATTGAGAATTGAAAATATTGGTGAAAGCAATCTAAATGTTTTATATAATTGCACTGTGGCCAGCACGGGAGGCACAGACACCAAAAGCTTCATCTTGGTGAGAAAAGCAGACATGGCTGATATCCCAGGCCACGTCTTCACAAGAGGAATGATCATAGCTGTTTTGATCTTGGTGGCAGTAGTGTGCCTAGTGACTGTGTGTGTCATTTATAGAGTTGACTTGGTTCTATTTTATAGACATTTAACGAGAAGAGATGAAACATTAACAGGTAACACATATAATGCTGGAATTTCTTACCTTATGTTCTCATTAAGAAATCAGATAAATA) using a blastn search against the nucleotide collection (nr/nt) or expressed sequence tags (EST) databases limited to *H. sapiens*. Identified sequences of interest were further evaluated with the 'Mapviewer' tool from NCBI, and performing BLAST alignments against the human *IL18R1* reference sequence ([NM_003855.2](NM_003855.2)/[ENST00000233957](ENST00000233957)) and predicted intron insert (intron 8-9 from [ENST00000233957](ENST00000233957)) to assess whether these sequences could represent a putative human type II IL-18R*α* transcript.

Samples and RNA extraction
--------------------------

Experimental verification of human and rat type II *IL18R1* transcripts was performed by RT-PCR on human and rat cDNA samples. Human whole blood was obtained from one of the authors (CB), a 32-year-old male of European descent, by venipuncture using a Vacutainer^®^ tube containing potassium Ethylenediaminetetraacetic acid (EDTA) (BD Biosciences, USA). RNA was extracted using Zymo Research whole-blood RNA MiniPrep™ tubes (catalogue number R1020; Zymo Research, USA) without prior lysis of red blood cells, according to manufacturer's instructions. Rat lung samples were obtained from three adult male Sprague-Dawley rats for verifying expression of a rat type II *IL18r1* transcript, with samples collected fresh after decapitation, placed on dry ice, and transferred to a −80°C freezer until processing. Rats were obtained from the Hercus-Taieri Resource Unit, Dunedin, New Zealand which maintains a colony of Sprague-Dawley rats (Strain Code: 400, Crl:SD) originally sourced from Charles River Laboratories (Wilminton, MA, USA) and were from two litters with a mean age of 97 days (101, 89 and 101 days, rats A, B, and C, respectively) and mean weight 459 g (472 g, 443 g, and 461 g, respectively). Rats were housed in group housing with other littermates on 1/4″ Bed-o'Cobs^®^ bedding from The Anderson Lab Bedding (The Andersons, Inc., Maumee, Ohio) and fed Rat and Mouse Cubes from Specialty Feeds (Glen Forest, Western Australia). Rats had not been involved in previous experimental procedures. Lung samples were homogenized using a Qiagen TissueLyser II (catalogue number 85300; Qiagen, Germany) in QIAzol Lysis reagent (catalogue number 79306) and RNA extracted with Qiagen RNeasy Plus Universal mini spin columns (product number 73404) according to manufacturer's instructions.

Reverse transcription
---------------------

Reverse transcription was performed using Superscript™ III reverse transcriptase (product number 18080-044; Invitrogen) in 20 µl reactions containing: 50 ng of random hexamers, approximately 700 ng of total RNA for human blood sample or 3,000 ng for rat lung samples, 10 nmol of dNTPs, 0.1 µmol of DDT, 4 µl of 5 × first strand buffer, 200 units of Superscript™ III (substituted for DEPC (diethylpyrocarbonate)-treated H~2~O for RT- control samples), 40 units of RNaseOUT™(product number 10777-019; Invitrogen) and DEPC-treated H~2~O as needed to complete reaction volumes. Random hexamers, dNTPs, and total RNA were first incubated at 65 °C for five minutes for annealing of hexamers, and after cooling the remaining reagents were added and samples incubated at 25 °C for 5 min, followed by 50 °C for 60 min, and reactions terminated by incubation at 70 °C for 15 min. For rat samples, following reverse transcription, 2 units of RNase H (product number 18021-014; Invitrogen) was added and samples incubated for 20 min at 37 °C to remove any remaining complementary RNA.

Primer design
-------------

Primers were designed to amplify human and rat *IL18R1*/*IL18r1* reference sequence transcripts as shown in [Table 1](#table-1){ref-type="table"}. For amplifying putative type II IL-18R*α* transcripts, reverse primers were designed against the predicted inserted intron sequences. For rat samples, the same reverse primer as used by [@ref-2] for identifying type II mouse IL-18R*α* was used with three nucleotides modified to match the homologous rat intron sequence. For human samples, the reference *IL18R1* sequence ([NM_003855.2](NM_003855.2)/[ENST00000233957](ENST00000233957)) was truncated to exon 8 and combined with the first 300 nt of intron 8-9 (given that the murine type II IL-18R*α* sequence incorporates the first 362 nt from the homologous mouse intron) to provide a predicted mRNA transcript sequence, and primers designed using Primer-BLAST (<http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi>) ensuring a reverse primer was placed in the intron insert ([Table 1](#table-1){ref-type="table"}). For human samples, the reference *IL18R1* sequence was used as a positive control to ensure expression of the *IL18R1* gene could be detected in blood samples. For rat samples, primers against *Actb* were included as controls.
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###### Primer details for amplification of putative type II IL-18r1 transcripts in rat and human samples.

![](peerj-02-560-g007)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Species   Transcript        Primer     Primer sequence    Primer binding                                                   Expected product size    
  --------- ----------------- ---------- ------------------ ---------------------------------------------------------------- ------------------------ --------
  Human     IL18r1            F primer   ACGCCGAGTTTGAA\    [ENST00000233957](ENST00000233957)/ [NM_003855.2](NM_003855.2)   545--568                 687 bp
                                         GATCAGGGGT                                                                                                   

                              R primer   CCCTGGGCAAAATCT\   [ENST00000233957](ENST00000233957)/ [NM_003855.2](NM_003855.2)   1,209--1,231             
                                         CCACAGCA                                                                                                     

            IL18r1 type II\   F primer   ACGCCGAGTTT\       [ENST00000233957](ENST00000233957)/[NM_003855.2](NM_003855.2)    545--568                 874 bp
            splice variant               GAAGATCAGGGGT                                                                                                

                              R primer   ATACAGTTCCTG\      [NT_022171.15](NT_022171.15) [^a^](#table-1fn1){ref-type="fn"}   7,680,768--7,680,789     
                                         GGCCCGAGCA                                                                                                   

  Rat       IL18r1 type II\   F primer   CCAACGAAGAAG\      [NM_001106905.2](NM_001106905.2)                                 1,269--1,289             463 bp
            splice variant               CCACAGACA                                                                                                    

                              R primer   AGCACGGGACA\       [AC_000077.1](AC_000077.1) [^b^](#table-1fn2){ref-type="fn"}     40,496,516--40,496,536   
                                         TGTGAGGAGA                                                                                                   

            Actb              F primer   TACAACCTTCTT\      [NM_031144.2](NM_031144.2)                                       28--51                   649 bp
                                         GCAGCTCCTCCG                                                                                                 

                              R primer   TGTAGCCACGC\       [NM_031144.2](NM_031144.2)                                       657--676                 
                                         TCGGTCAGG                                                                                                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes.**

Alternative R primer genomic coordinates: GRCh37, chromosome 2: 103,006,939--103,006,960.

Alternative R primer genomic coordinates: RGSC3.4, chromosome 9: 39,652,714--39,652,734.

PCR and gel electrophoresis
---------------------------

Polymerase chain reactions (PCR) for amplification of human transcripts were performed using Platinum^®^ *Taq* high fidelity and AccuPrime™ *Taq* polymerases (catalogue number 12567-012; Invitrogen, henceforth Platinum and Accuprime *Taq*). Reactions for human samples involving Platinum *Taq* contained 10 nmol dNTPs, 0.1 µmol MgSO~4~, 5 µl of 10 × buffer, 1 U of polymerase, approximately 100 ng of cDNA (assuming a 100% conversion of total RNA to cDNA during reverse transcription), 10 pmol each of forward and reverse primers, and made up to a total volume of 50 µl using DEPC-treated H~2~O. For reactions involving Accuprime *Taq*, 5 µl of 10 × 'buffer I', 10 pmol each of forward and reverse primers, approx 100 ng of cDNA, and 2 U of Accuprime *Taq* were combined with DEPC-treated H~2~O up to a total 50 µl volume.

Polymerase chain reactions for rat transcripts were performed in 50 µl reactions using Platinum *Taq* polymerase SuperMix (catalogue number 12567-012; Invitrogen), incorporating 45 µl of SuperMix (containing polymerase and dNTPs), 1 µl of DEPC-treated H~2~O, 20 pmol each of forward and reverse primers, and approximately 300 ng of cDNA.

Reverse transcription and PCR reactions were perfomed in polypropylene PCR tubes (catalogue number PCR-02D-L-C; Axygen, USA) and carried out on either a Biometra TProfessional Basic thermocycler (order number 070-701; Biometra, Germany) or an MJ Research Minicycler™ (Model PTC-150HB; MJ Research Inc, Watertown, MA, USA). For amplifications of human IL-18r1 reference and type II transcripts, thermocyclers were set to 94 °C for 2 min for initial denaturing, followed by 35 cycles of 94 °C for 30 s as a denaturing step, 55 °C for 30 s as an annealing step, and 68 °C for 1 min for extension. Reactions were terminated with a final extension step of 68 °C for 3 min and cooled to 10 °C for 3 min. For amplification of cDNA from rat samples, thermocycler settings were: 94 °C for 2 min for initial denaturing, followed by 35 cycles of 94 °C for 30 s as a denaturing step, 55 °C for 30 s for primer annealing, and 72 °C for 1 min for polymerase extension, followed by a final extension step of 72 °C for 5 min.

Gel electrophoresis of RT-PCR products was performed on 3% agarose gels (catalogue number 15510-027; Invitrogen Ultrapure™ agarose) using Qiagen GelPilot DNA loading dye (catalogue number 239901; Qiagen, Germany) and 100 bp DNA ladder (SKU\#15628-019; Invitrogen). Images were captured on a digital camera connected to a Biometra BioDoc Analyzer running BioDoc Analyzer 2.1 software.

PCR product purification and Sanger sequencing
----------------------------------------------

PCR products were purified for sequencing using Zymo Research DNA Clean & Concentrator™ −5 spin columns (catalogue number D4013; Zymo Research, USA) and sequenced at a commercial sequencing service (Genetic Analysis Services; University of Otago, Dunedin, New Zealand), which performs Sanger sequencing using an ABI 3730xl DNA Analyser with BigDye^®^ Terminator Version 3.1 Ready Reaction Cycle Sequencing Kits. Chromatograms of sequencing products were used 'as is', with no attempt to manually correct ambiguous reads or base calling errors, and are included in [File S1](#supp-1){ref-type="supplementary-material"} (Chromatograms S1--S8). Sanger sequencing products and predicted IL-18r1 type II transcript sequences were compared in Geneious Basic (v5.6.; <http://www.geneious.com/>) using the 'Geneious Alignment' algorithm with default settings (65% similarity cost matrix, Gap open penalty of 12, Gap extension penalty of 3, assessed by global alignment with free end gaps). Consensus sequences from forward and reverse primer reads have been submitted to Genbank with accession numbers [KM264374](KM264374) (Human type II *IL18R1* amplified with Accuprime *Taq*, shown in [Fig. 2](#fig-2){ref-type="fig"}), [KM264375](KM264375) (Human type II *IL18R1* amplified with Platinum *Taq*, shown in [Fig. 2](#fig-2){ref-type="fig"}), [KM264376](KM264376) (Rat type II *IL18r1* sequenced from Rat B, shown in [Fig. S1](#supp-2){ref-type="supplementary-material"}), [KM264377](KM264377) (Rat type II *IL18r1* sequenced from Rat C, shown in [Fig. S1](#supp-2){ref-type="supplementary-material"}).

Bioinformatics assessment of human TIR domain
---------------------------------------------

To assess the similarity between the predicted C-terminal portion of human type II IL-18R*α* and other members of the IL-1 receptor family, protein sequences of the predicted human type IL-18R*α*, interleukin-18 receptor 1 precursor ([NP_003846.1](NP_003846.1)), interleukin-18 receptor accessory protein precursor ([NP_003844.1](NP_003844.1)), interleukin-1 receptor type 1 precursor ([NP_000868.1](NP_000868.1)), interleukin-1 receptor-like 2 precursor ([NP_003845.2](NP_003845.2)), single Ig IL-1-related receptor ([NP_001128526.1](NP_001128526.1)), X-linked interleukin-1 receptor accessory protein-like 2 precursor ([NP_059112.1](NP_059112.1)), interleukin-1 receptor accessory protein-like 1 precursor ([NP_055086.1](NP_055086.1)), interleukin-1 receptor-like 1 isoform 1 precursor ([NP_057316.3](NP_057316.3)), interleukin-1 receptor type 2 precursor ([NP_775465.1](NP_775465.1)), and interleukin-1 receptor accessory protein isoform 1 precursor ([NP_002173.1](NP_002173.1)) were aligned using the MUSCLE (MUltiple Sequence Comparison by Log-Expectation) online tool from the European Bioinformatics Institute (Cambridgeshire, UK).

Comparison of human type I *IL18R1* (reference) and type II sequences
---------------------------------------------------------------------

Given similarities in the predicted amino acid sequence of human type II IL-18R*α* and the human IL-18R*α* reference protein sequence, the respective intron and exon nucleotides encoding these amino acids were assessed by EMBOSS (European Molecular Biology Open Software Suite) Water alignment (European Bioinformatics Institute, Cambridgeshire, UK).

Assessment of putative type II *IL18R1* nucleotide and type II IL-18R*α* amino acid sequences across multiple species
---------------------------------------------------------------------------------------------------------------------

In order to assess whether transcription of homologous introns into the *IL18R1* transcript in other species would also result in truncated receptors, we searched for species with known *IL18R1* genes by assessing homology with *H. sapiens* IL-18R*α* through the Ensembl database. We identified 45 proteins which were further assessed for ambiguous amino acid and nucleotide sequences or other characteristics which would limit their assessment, as detailed in [Table S1](#supp-4){ref-type="supplementary-material"}. For human *IL18R1* transcripts, the Ensembl records IL18R1-201/[ENST00000233957](ENST00000233957)/[ENSP00000233957](ENSP00000233957) were chosen as the comparator as these show 1:1 identity to the NCBI sequences [NM_003855.2](NM_003855.2)/[NP_003846.1](NP_003846.1) respectively. Two identified sequences in the Zebra Finch showed homology to the cytoplasmic domains of IL-18R*α*, but sequences lacked any extracellular domains and whether these form functional receptors is unknown; these were therefore excluded from further analysis. Two splice variants were identified in the Tasmanian Devil which arise through the differential use of exons and encode proteins which differ in the cytoplasmic region immediately following the transmembrane domain, similar to the difference between IL-18R*α* full length proteins and proteins predicted to be encoded by type II *IL18R1* transcripts in mice, rats and humans. Therefore, these may represent type I (reference sequence) and type II *IL18R1* splice variants in the Tasmanian Devil and were excluded from further analysis. Similarly, two splice variants were identified in the Turkey which arise through the differential use of exons, however the differences are limited and localized to the extracellular domain of the receptor, therefore only one of these was included in the analysis since both transcripts utilize the same exon structure in the portion which encodes the transmembrane and cytoplasmic domains of the receptor. After exclusions, 34 transcripts and amino acid sequences from 33 species were assessed by multiple sequence alignment to identify introns homologous to those unspliced in type II *IL18R1* sequences in the mouse, rat and human, and to predict hypothesized C-terminal domains of type II IL-18R*α* proteins. Multiple sequence alignments were performed using the MUSCLE tool available from the European Bioinformatics Institute (Cambridgeshire, UK) (EBI) and subsequently passed through the MView tool available from the European Bioinformatics Institute (Cambridgeshire, UK) for ease of visualization. Sequences were assessed through percent identities to human sequences as a reference and outputs are ordered anthropocentrically, i.e., according to similarity to human sequences. For assessment of insertion of an *Alu* transposable element in primate sequences, the human sequence surrounding the point of *Alu* insertion was run through the RepeatMasker online tool ([@ref-54]) to identify the *Alu* subfamily inserted, and the *AluY* sequence from the RepeatMasker site (<http://www.repeatmasker.org/AluSubfamilies/humanAluSubfamilies.html>) used in multiple sequence alignment against desired primate sequences using MUSCLE alignment. An analysis of evolutionary constraint across 29 mammalian species ([@ref-41]) includes overlap with 23 of the 33 species analysed here. Regions of high conservation within the human *IL18R1* gene intron 8-9, shown in [Fig. 6](#fig-6){ref-type="fig"}, were identified from the 29 mammals track of the University of California Santa Cruz (USCS) Genome Browser (<http://genomewiki.cse.ucsc.edu/index.php/29mammals>).

Nomenclature
------------

[@ref-2] label the murine *IL18r1* splice variant incorporating an unspliced intron 'type II' *IL18r1*, with the reference sequence becoming type I *IL18r1*. This nomenclature is continued here. In order to provide clarity between the splice variant mRNA transcript, which has been experimentally verified in the mouse ([@ref-2]) and in the rat and human in the current work, and the predicted protein sequences encoded by the detected transcripts, throughout the text mRNA transcripts are referred to as either type I or type II *IL18R1*/*IL18r1* (the mRNA products resulting from differential transcription of the *IL18R1*/*IL18r1* gene), with protein sequences as type I or type II IL-18R*α* (the mature full-length interleukin-18 receptor alpha reference protein or predicted truncated receptor protein, respectively).

Results and Discussion
======================

We examined the *Homo sapiens IL18R1* gene sequence ([ENST00000409599](ENST00000409599)) to first identify whether inclusion of an unspliced intron could give rise to a similarly truncated receptor. Transcription of intron 8-9 of the human *IL18R1* reference sequence (Ensembl [ENST00000233957](ENST00000233957), Genbank: [NM_003855.2](NM_003855.2); intron 8-9 equivalent to hg19 chromosome 2: 103,006,678--103,010,928) would be expected to translate to a protein with a novel 22 amino acid C-terminal followed by a stop codon ([Fig. 1](#fig-1){ref-type="fig"}), and thus generate a type II IL-18R*α* protein lacking much of the cytoplasmic domain, as predicted for murine type II IL-18R*α*.

![Schematic diagram of *IL18R1* reference sequence and aligned expressed sequence tags.\
*IL18R1* reference sequence ([ENST00000233957](ENST00000233957)/[NM_003855.2](NM_003855.2)) intron-exon structure aligned with three identified expressed sequence tags containing portions of intron 8-9. Shown above in boxed region is the expected protein coding sequence of a putative human *IL18R1* splice variant incorporating intron 8-9 of [ENST00000233957](ENST00000233957). Underlined nucleotides indicate those from the preceding exon 8. Codons are indicated by alternate grey shading of nucleotides. Incorporation of intron 8-9 would be expected to translate into a protein with a novel 22 amino acid C-terminal followed by a stop codon. First nucleotide shown in boxed region is nt 1132 from [ENST00000233957](ENST00000233957)/[NM_003855.2](NM_003855.2), first amino acid is residue 370 from [ENSP00000233957.1](ENSP00000233957.1)/[NP_003846.1](NP_003846.1).](peerj-02-560-g001){#fig-1}

![Schematic diagram of *IL18R1* reference sequence and aligned expressed sequence tags.\
*IL18R1* cDNA from human blood was amplified by PCR using two polymerases, Platinum and Accuprime Taq as indicated, using the primer pairs shown in [Table 1](#table-1){ref-type="table"} to amplify the *IL18R1* reference transcript ('*IL18R1*', expected product size 687 bp) or predicted human type II *IL18R1* splice variant ('type II', expected product size 847 bp). 'RT+' and 'RT−' indicate PCR template generated with the addition of reverse transcriptase or without, respectively. Left hand lane shows 100 bp DNA ladder; brighter band towards the centre of the gel is 600 bp.](peerj-02-560-g002){#fig-2}

In order to investigate whether an mRNA sequence incorporating intron 8-9 had been previously observed, we performed BLAST searches for expressed sequence tags or nucleotide sequences using a 362 nt portion of the expected nucleotide sequence, covering the first 60 nucleotides of intron 8-9 preceded by the coding sequences of the two upstream exons. This revealed three sequences of interest with overlap between exon and intron nucleotides (BG541512.1, BG540341.1, and BG542027.1; [Fig. 1](#fig-1){ref-type="fig"}). Of these, BG540341.1, and BG542027.1 show continuous readthrough of exon-intron sequences and could possibly represent genomic sequences. Of note, BG542027.1 represents a sequence beginning in exon 8 of the human IL18r1 reference sequence and aligns to the first 357 nt of the subsequent intron 8-9, up to nt 436 of BG542027.1, which is a total of 697 nucleotides and is noted to have high quality read up to nt 430. This aligned intronic region is similar to the length of inserted intronic sequence reported for murine type II *IL18R1*, which incorporates the first 362 nt of the homologous murine intron. BG541512.1, a cDNA sequence from human lung tissue submitted by the Mammalian Genome Collection Project, represented the longest of the identified sequences and showed reasonable similarity to the expected sequence of human type II *IL18R1*, incorporating nt 475-1135 of [ENST00000233957](ENST00000233957)/[NM_003855.2](NM_003855.2) (representing a continuous read incorporating a portion of exon 3 through exon 8) and approximately 140 bp of intron 8-9 (represented schematically in [Fig. 1](#fig-1){ref-type="fig"}). These data are consistent with the possibility that an alternate transcript incorporating intron 8-9 is present in humans.

In order to experimentally verify whether a human type II *IL18R1* transcript could be detected, RT-PCR amplification of cDNA from human blood was performed, utilizing a forward primer placed within exon 4 and a reverse primer in intron 8-9 of [ENST00000233957](ENST00000233957), in order to exclude the possibility of amplifying genomic sequences. Gel electrophoresis of RT-PCR products revealed a band of the expected size for a putative type II *IL18R1* transcript ([Fig. 2](#fig-2){ref-type="fig"}). Chromatograms showed a sudden drop in read quality around a CAG deletion which has been previously reported in humans ([@ref-64]), consistent with a heterozygous indel ([@ref-8]) (see [File S1](#supp-1){ref-type="supplementary-material"}). Despite the drop in read quality, nucleotide sequences in lower quality read portions aligned well with the predicted human type II *IL18R1* transcript sequence, and non-overlapping regions of high quality read on both sides of the indel from sequencing with forward and reverse primers aligned with the predicted sequence (not shown), demonstrating the RT-PCR product was indeed the predicted human type II *IL18R1* transcript and incorporates previously intronic 5′ nucleotides of intron 8-9. Assessment of identity with the predicted human type II *IL18R1* transcript is shown in [Table 2A](#table-2){ref-type="table"}.
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###### Analysis of Sanger sequencing products for RT-PCR of human (A) and rat (B) IL-18r1 type II transcripts.

Sequencing products were compared with predicted IL-18r1 type II sequences derived from reference human and rat genes using Geneious Basic (v5.6.; <http://www.geneious.com/>). For human sequences, two deviations from the reference sequence were noted: rs1035130, and an nt 950 CAG deletion as reported by [@ref-64]. For rat sequences, a presumed SNP was identified which was consistent across both samples and in both sequencing directions at high read quality, present at nucleotide 39,652,571 of chromosome 9 (*G* \> *A*; rat genome Baylor 3.4/rn4 build). In both cases, predicted sequences were edited prior to alignment to account for these variations in the tables below. Raw chromatograms are included in [File S1](#supp-1){ref-type="supplementary-material"}.
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  \(A\)                                                       
  --------------- --------- ---- --------- ---- --------- --- --------
  Platinum Taq    Forward   86   753/875   94   826/875   3   32/875
                  Reverse   88   773/877   94   832/877   3   32/877
  Accuprime Taq   forward   79   699/878   89   788/878   4   36/878
                  Reverse   83   736/877   91   805/877   3   33/877

  \(B\)                                               
  ------- --------- ---- --------- ---- --------- --- --------
  Rat B   Forward   91   427/466   92   429/466   6   31/466
          Reverse   91   427/466   91   428/466   7   35/466
  Rat C   Forward   91   427/465   92   430/465   6   31/465
          Reverse   90   423/467   91   426/467   7   37/467

Similar experiments conducted using cDNA isolated from lung tissue of Sprague-Dawley rats showed the presence of a type II *IL18r1* splice variant transcript in this species as well ([Fig. S1](#supp-2){ref-type="supplementary-material"} and [Table 2B](#table-2){ref-type="table"}). Whereas the mouse ([@ref-2]) and rat type II IL-18R*α* splice variants are predicted to encode 5 amino acids and result in truncated receptors which lack the TIR domain characteristic of members of the interleukin-1/toll-like receptor superfamily, the predicted sequence of human type II IL-18R*α* was noted to encode amino acids similar to 'Box 1' of the TIR domain ([@ref-21]) ([Fig. 3A](#fig-3){ref-type="fig"}). Given the similarity in protein coding sequences, nucleotide sequences from intron 8-9 (encoding the C-terminal of the predicted human type II IL-18R*α*) were compared with those of exon 9 (which encodes the beginning of the TIR domain in the human type I *IL18R1* transcript) by pairwise alignment ([Fig. 3B](#fig-3){ref-type="fig"}). Intron 8-9 exhibits similarity to exon 9, with a number of conserved codons. This suggests these two DNA segments may have arisen through duplication of a previous primordial single region.

![Comparison of human type I and type II *IL18R1*.\
(A) C-terminal ends of human IL-18R*α* and predicted type II IL-18R*α* amino acid sequences. First amino acid, underlined, corresponds to residue 370 from [ENSP00000233957.1](ENSP00000233957.1)/[NP_003846.1](NP_003846.1). Shown in red is the amino acid at which the IL-18R*α* and predicted type II IL-18R*α* sequences diverge, which is encoded across an exon/exon and exon/intron boundary in the case of the reference sequence and predicted type II sequence, respectively. Between the two sequences, similar residues are shown with the region of IL-18R*α* corresponding to 'Box 1' of the TIR domain ([@ref-21]) indicated. (B) shows pairwise alignment by EMBOSS Water (European Bioinformatics Institute, Cambridgeshire, UK) of the nucleotides from exon 9 of the human *IL18R1* reference sequence ([ENST00000233957](ENST00000233957)/[NM_003855.2](NM_003855.2)) with those of intron 8-9. Codons are indicated by alternating grey shading, with the initial G nucleotide shown in brackets being the final nucleotide from exon 8 (nt 1135 of [ENST00000233957](ENST00000233957)/[NM_003855.2](NM_003855.2)). Above and below the respective sequences are shown the corresponding amino acid sequences.](peerj-02-560-g003){#fig-3}

IL-18 belongs to the IL-1 family of cytokines, and is highly homologous to IL-1, sharing similarities in processing, receptor function and downstream signalling ([@ref-17]; [@ref-18]). In the case of IL-1, a truncated ligand-binding receptor, IL-1R2 (aka IL-1RII), forms a "decoy receptor" lacking the intracellular TIR domain and unable to induce downstream signalling ([@ref-15]). Multiple sequence alignment of members of the human interleukin-1 receptor family ([Fig. 4](#fig-4){ref-type="fig"}) shows that IL-1R2 encodes an amino acid sequence with a C-terminal showing similarities to the 'Box 1' segment of the TIR domain. Similarly, the human type II *IL18R1* transcript would be expected to encode a protein with a C-terminal showing similarity to the 'Box 1' segment, terminating just prior to the 'Box 2' segment of the TIR domain, suggesting the predicted type II IL-18R*α* protein forms an truncated receptor for IL-18, analogous to the IL-1R2 receptor for IL-1.

![Multiple sequence alignment of human IL-1 receptor family members.\
The predicted protein coding sequence of human type II IL-18R*α* aligned with IL-1 receptor family members. Shown are the amino acid residues surrounding the beginning of the TIR domain, where the sequence of type II IL-18R*α* diverges from the reference sequence. Boxed regions are the 'Box 1' and 'Box 2' motifs present in the TIR domain.](peerj-02-560-g004){#fig-4}

The truncated inhibitory receptor for IL-1, IL-1R2, is found across a wide range of species, and given a conserved role for IL-18 and its receptor in many species, a similar inhibitory receptor for IL-18 could also be conserved throughout evolution. The previous findings of [@ref-2] showed the existence of a murine type II IL-18R*α* and our findings of homologous splice variants in human and rat species suggested that insertion of an unspliced intron during transcription of the IL18r1 gene could form a mechanism of generating an inhibitory receptor for IL-18 across a more widespread range of species. We therefore asked whether transcription of homologous intron sequences would be expected to encode truncated splice variants of IL-18R*α* across species for which gene records for *IL18R1* were available.

We identified *IL18R1* gene sequences for 33 species ([Table S1](#supp-4){ref-type="supplementary-material"}, including human, rat and mouse) from which 34 transcripts and proteins were aligned to identify homologous intron sequences to those experimentally verified to be transcribed in mouse, rat, and human type II *IL18R1* splice variants. Alignment of the nucleotide sequences of the preceding exon (equivalent to exon 8 of human *IL18R1*) and corresponding protein sequences showed a conserved predicted reading frame across species ([Fig. S2](#supp-3){ref-type="supplementary-material"}). Analysis of predicted C-terminal amino acid sequences which would be translated from identified intron sequences is shown by multiple sequence alignment in [Fig. 5](#fig-5){ref-type="fig"}. While the predicted mouse and rat protein sequences consist of a short C-terminal tail of 5 amino acids, in many species predicted sequences are a similar length to that predicted in humans with similarities to the 'Box 1' motif of the TIR domain. As expected, based on similarities in intron nucleotide sequences, predicted primate amino acid sequences were similar to the human sequence with the notable exception of the predicted Orangutan sequence, where an adenine in place of a thymine results in an adenosine codon in the Orangutan sequence where other members of the primate family show a stop codon ([Fig. 6A](#fig-6){ref-type="fig"}).

![Multiple sequence alignment of putative type II IL-18R*α* C-terminal ends across multiple species.\
Sequences are colour-coded as per MView (European Bioinformatics Institute, Cambridgeshire, UK): the human sequence is coloured according to residue properties, as indicated under 'Key', with residues from other species identical to human coloured with the same schema. Orangutan, Armadillo and Tarsier sequences are truncated by the indicated number of amino acids. Percentages reflect percent identity to human sequence as a reference.](peerj-02-560-g005){#fig-5}

![Alignment of homologous intron sequences from *IL18R1* across a range of species.\
(A) When the reading frame is continued into the intron sequences, stop codons (red shading) are encountered shortly into the intron sequence, including a conserved stop codon position which resides within a region of high conservation (grey shading) as identified by [@ref-41]. Further downstream (B) an apparent conserved polyadenylation sequence (red shading, PolyA) is apparent, within a region of high conservation identified by [@ref-41] (grey shading). A proposed transcription termination site (TTS) is indicated by the dotted line.](peerj-02-560-g006){#fig-6}

Of note, an *Alu* insertion is present in the homologous introns of many primate species assessed including the homologous human, orangutan, gibbon, gorilla, chimpanzee and macaque introns, but not in other species. Its presence in this group of primates, but not other primates assessed (Marmoset, Mouse Lemur, Bushbaby or Tarsier), would place its insertion at a last common ancestor in the Catarrhini parvorder following the separation of the Catarrhini and Platyrrhini parvorders, which is estimated to have occurred some 35 million years ago (mya) ([@ref-50]) to 42 mya ([@ref-57]), at some stage in the mid- to late-Eocene. Assessment of the human intron sequence with RepeatMasker ([@ref-54]) identified the insertion as belonging to the *Alu*Y subfamily with 14 transitions, 2 transversions, and one gap of 2 nucleotides. Evident surrounding the complete *Alu*Y sequence is a target site duplication (TSD) and oligo(dA)-rich tail from *Alu* insertion. Upstream from the *Alu* insertion is a polyadenylation signal (PolyA; AATAAA) which is largely conserved across primates and also across the wider spectrum of species assessed ([Fig. 6B](#fig-6){ref-type="fig"}). The expressed sequence tag BG542027.1 shows alignment of 357 nucleotides into the human intron 8-9 of [ENST00000233957](ENST00000233957), at a point just downstream of this polyadenylation signal, which also aligns with the final nucleotide in the mouse type II IL-18r1 transcript (BC023240) before the polyadenine tail and thus is likely to represent the transcription termination site of human type II *IL18R1*. A recent analysis by [@ref-41] identified regions of evolutionary constraint across 29 mammalian species and revealed five highly-conserved segments present in human *IL18R1* intron 8-9 (excluding the initial 5′ highly conserved intronic nucleotides), four of which map to within or immediately adjacent to the human *IL18R1* type II transcript. These represent two regions of overlap with identified stop codon sequences (one of which is depicted in [Fig. 6A](#fig-6){ref-type="fig"}), another surrounding the polyadenylation signal ([Fig. 6B](#fig-6){ref-type="fig"}), and a fourth downstream of the predicted transcription stop site, which we hypothesize is likely to play a role in transcription termination. This cross-mammalian conservation is likely to represent selection pressure acting at these loci.

We have found experimental evidence of the existence of a type II *IL18R1* transcript in both human and rat species. In both of these cases, as well as the previously reported type II *IL18r1* transcript in the mouse (BC023240) ([@ref-2]), the splice variants arise from the insertion of unspliced homologous introns. Our analysis of the coding sequences of homologous introns in a wider array of species suggests that this mechanism of generating truncated versions of the IL-18R*α* subunit could be evolutionarily conserved. Whether or not truncated splice variants are actually transcribed and translated in these species will need to be experimentally verified in each case. However, the regions of conservation identified here and previously by [@ref-41] demonstrate the existence of selection pressure which is highly suggestive of a wider utilization of similar alternative transcripts beyond the mouse, rat and human.

While predicted rat and mouse type II IL-18R*α* amino acid sequences consist of a short C-terminal tail immediately following the transmembrane domain, the predicted amino acid sequences in humans and many other species exhibit similarity to the initial region of the TIR domain incorporating the Box 1 motif. In the human ([Fig. 4](#fig-4){ref-type="fig"}) it can be seen that IL-1R2 and the type II IL-18R*α* splice variant appear to form homologous truncated receptors, with both arising in the ligand-binding subunit of the respective receptor complexes (as opposed to the accessory protein subunits), and both encoding short C-terminal domains with similarity to the 'Box 1' sequence of the TIR domain. Whereas the truncated IL-1R2 receptor is transcribed from a different gene than that encoding IL-1R1, in the case of IL-18R*α*, a similar truncated receptor is predicted to be encoded by the use of a splice variant of the gene encoding the full-length receptor. Previously, IL-18 binding protein (IL-18 BP) has been noted as showing similarity to IL-1R2 in structure and function ([@ref-46]; [@ref-20]), with one study suggesting that they may share evolutionary origins ([@ref-63]). However our analysis suggests that, at least in terms of present day predicted protein sequences, IL-1R2 is in fact more similar to the predicted type II IL-18R*α*. The similarity of the coding sequences of exon 9 and intron 8-9 in the human *IL18R1* gene sequence ([ENST00000233957](ENST00000233957)/[NM_003855.2](NM_003855.2)) suggests that these gene sequences may have arisen through innovation, amplification and divergence ([@ref-7]) of what was once a single genetic locus. Given similarities between intron sequences across the range of species assessed here, this explanation seems more likely than convergent evolution, and would also place such a duplication event at a very ancient timepoint in the evolutionary scale.

Exactly what role the Box 1-like motif plays in the relative functions of human versus rodent type II IL-18R*α* is unknown. In the related IL-1R1, mutations in Box 1 have been shown to disrupt pro-inflammatory signalling ([@ref-53]), showing that this conserved domain is critical for normal receptor function. Crystal structures of the related Toll-like receptors 1 and 2 (TLR1/TLR2) and interleukin-1 receptor accessory protein-like 1 (IL1RAPL1) show that the initial Box 1 portion of these receptors forms a *β*-strand with the following residues forming an *α*-helix prior the second *β*-strand formed by the Box 2 motif ([@ref-66]; [@ref-36]). Particularly noteworthy are the findings of [@ref-36] who assessed the crystal structure of IL1RAPL1, another member of the IL-1 family of receptors. In their analysis, constructs of human IL1RAPL1 lacking almost the entire cytoplasmic domain (including only amino acids 1--410) transfected into HEK293 cells were still able to activate JNK signalling. These constructs would include almost all of the Box 1 domain, terminating with the residues DAYLS (compare [Fig. 4](#fig-4){ref-type="fig"}), and thus form receptors truncated at a similar point as IL-1R2 and the putative human type II IL-18R*α*. While there is no evidence that IL-1R2 can induce JNK signalling, a number of studies have shown IL-18 is able to activate JNK signalling ([@ref-13]; [@ref-49]; [@ref-51]; [@ref-3]). The question which then arises is whether a truncated receptor for IL-18 would still be capable of inducing JNK signalling, as appears to be the case for a truncated IL1RAPL1 receptor. The work of [@ref-13] showed in rat aortic smooth muscle cells that IL-18-induced JNK activation occurs downstream of a variety of intermediate signalling events including Myd88 activation, and likewise [@ref-1] showed a lack of IL-18-induced JNK activation in Myd88-/- cells; both provided support for IL-18 activation of JNK occurring downstream of Myd88 recruitment. Whether a truncated IL-18R*α* subunit would be capable of forming dimers with IL-18R*β* and further complexes with Myd88 is unclear, but seems unlikely given mechanisms of action involving dimerisation of TIR domains.

Of particular relevance to these results are recent works investigating the processes controlling differential gene splicing. Given that multiple polyadenylation signals are often present within a gene and transcription occurs in a 5′ to 3′ direction, the question of how longer transcripts are generated when there are coexistent polyadenylation signals at more 5′ sites has been a topic of investigation. Studies have recently shown that U1 small nuclear RNA (snRNA), which is known for its role in splicing through recognition of 5′ splice sites, also plays a key role in suppressing the transcription of shorter transcripts associated with more 5′ polyadenylation signals, and thus regulates transcript length for genes with multiple polyadenylation signals ([@ref-34]; [@ref-44]; [@ref-6]). Interestingly, autoantibodies to U1 snRNA occur in a number of autoimmune disorders ([@ref-11]; [@ref-35]), particularly mixed connective tissue disease and systemic lupus erythematosus, diseases in which altered IL-18 activity or its downstream effector, interferon-gamma (IFN-*γ*), have been observed ([@ref-4]; [@ref-9]; [@ref-24]). [@ref-6] showed that depletion of U1 snRNA through RNA knockdown results in shorter transcripts corresponding to more 5′ polyadenylation signals. Given these findings, autoantibodies to U1-snRNA would be expected to result in an increase in the proportion of type II to type I *IL18R1* transcription and a reduction in IL-18 activity (assuming type II *IL18R1* transcripts form truncated receptors incapable of downstream signalling). In addition, rapidly dividing cells such as those of the immune system exhibit reduced U1-snRNA to transcript ratios ([@ref-44]) and shorter transcript lengths. Newly-dividing immune cells may therefore also express higher amounts of type II IL-18r1 transcripts, which could give rise to important differences in IL-18 responsiveness in dividing vs. mature cells. Neoplastic cells are also reknowned for their rate of cell division, and by the same mechanism a reduction in responsiveness to IL-18 through increased type II *IL18R1* transcription may be of relevance for efforts to treat cancer with IL-18 therapies ([@ref-26]; [@ref-56]).

Previous research has identified a seemingly paradoxical increase in inflammatory signalling in cells lacking the IL-18R*α* chain ([@ref-40]; [@ref-45]). The anti-inflammatory cytokine IL-37 is able to bind the IL-18R*α* chain, and the lack of signalling from IL-37 may underlie the reported phenotype of IL-18R*α*-deficient cells. However, the existence of an inhibitory splice variant of IL-18R*α* would also raise the possibility that this phenotype may derive in part from a lack of type II IL-18R*α*. Whether IL-37 may in fact preferentially bind or act through a truncated IL-18R*α* subunit is another possibility worth investigating.

The existence of an *Alu* insert in various primate *IL18R1* gene sequences is in many ways unsurprising as it is well established that *Alu* sequences have undergone rapid expansion in the primate family ([@ref-5]; [@ref-16]; [@ref-31]). The presence of the *Alu* insert may be of relevance to the regulation of type II *IL18R1* transcription in primates; *Alu* inserts have been shown to contain various regulatory regions, such as retinoic acid receptor motifs ([@ref-38]; [@ref-61]) (which are largely conserved in the human *IL18R1* gene sequence), and various studies suggest a role for *Alu* insertions in the regulation of gene expression in immune cells ([@ref-25]; [@ref-28]) with *Alu* repeats hypothesized as giving rise to evolutionary changes in primates and humans ([@ref-16]). While a number of studies report a role for *Alu* insertions in promoter sequences as regulators of gene function ([@ref-32]; [@ref-47]; [@ref-62]; [@ref-22]; [@ref-39]), there is evidence that insertion into other non-promoter regions is also capable of regulating gene transcription. For example, an intronic *Alu* element in the human CD8*α* gene regulates its transcription in T-cells ([@ref-28]), *Alu* elements in the 3′ UTR of genes are involved in a mechanism of Staufen 1 (STAU1)-mediated mRNA decay ([@ref-27]) and associate with lower levels of transcription ([@ref-23]), and an *Alu* repeat in the 3′ region of the human growth hormone influences its transcription rate ([@ref-60]). Of particular interest to the scenario in the human *IL18R1* gene, where the *Alu* insert occurs downstream of the 3′ UTR, is a similar situation in the human APOA2 gene; in that case an *Alu* insert 305 nucleotides downstream of the polyadenylation signal of the APOA2 gene ([@ref-37]) (compared to 79 nucleotides from polyadenylation signal to 5′ TSD in human type II *IL18R1*) contains an SNP (rs12143180) leading to a MspI restriction polymorphism which is associated with lipoprotein levels ([@ref-14]). These findings provide an example of an *Alu* element downstream of a gene regulating phenotype, and raise the possibility that the *Alu* element downstream of the human type II *IL18R1* transcript could influence its transcription. *Alu* elements can also be subject to methylation ([@ref-65]; [@ref-12]), and differential methylation could conceivably form a mechanism by which type II IL-18r1 transcription could be limited to select cells or stages of cellular development. If this *Alu* element does play a role in the regulation of type II *IL18R1* transcription in humans, the lack of an equivalent *Alu* element in commonly used rodent laboratory animals suggests that this may form an important point of difference between IL-18 function in humans and rodents, and limit the generalization of results between these species.

One limitation of our study is that we have not verified whether human and rat type II *IL18R1*/*IL18r1* transcripts are indeed translated into type II IL-18R*α* proteins. This has also not been shown yet for murine type II *IL18r1* transcripts. Antibodies for the detection of IL-18R*α* will need to be carefully validated for their respective binding abilities of type I and the putative type II IL-18R*α* proteins in order to enable experimentation into their presence in different tissue types. In addition, from our results the source of the identified type II *IL18R1* transcripts has not been assessed in terms of examining specific cell types expressing this mRNA transcript. The type I reference *IL18R1* transcript is expressed in a variety of cell types, and identifying which of these also express type II *IL18R1* will be an important step in determining the physiological role of type II *IL18R1*. Neither have we specifically identified the transcription start or termination sites for human or rat type II *IL18R1*/*IL18r1* transcripts. However, based on the cDNA record BG542027.1, alignment with mouse type II *IL18r1*, and the site of a putative polyadenylation signal, we conclude that the transcription termination site for human type II *IL18R1* occurs 357 bp into the inserted intron sequence (see [Fig. 6](#fig-6){ref-type="fig"}).

Conclusions
===========

In conclusion, we have identified alternative transcripts of the human and rat *IL18R1*/*IL18r1* genes, analogous to the previously reported type II *IL18r1* transcript in the mouse ([@ref-2]). These transcripts are likely to produce truncated proteins lacking most of the intracellular domain, which would be expected to result in altered signalling properties and thus may influence IL-18 activity *in vivo*. We also provided evidence that transcription of homologous intron regions in other species could give rise to similar truncated transcripts and that these genetic regions shown signs of selection pressure, indicating that this may be a mechanism of regulating IL-18 signalling which is conserved across different branches of the evolutionary tree. Given the apparent similarity between predicted protein sequences for these truncated IL18R*α* isoforms and IL1R2, and hence a similar predicted function as a receptor which fails to elicit intracellular signalling, we suggest adopting the nomenclature IL18R*α*2 to refer to these splice variant isoforms.
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###### Raw chromatograms from Sanger sequencing of PCR products

Dataset S1---Chromatograms from Sanger sequencing of IL-18r1 type II PCR products shown in [Figs. 2](#fig-2){ref-type="fig"} and S1.
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Click here for additional data file.
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###### RT-PCR results for detection of a type II *IL18r1* transcript in rat lung tissue

A 100 bp ladder is shown in the left lane, followed by reverse transcriptase positive (RT+) and negative (RT−) samples from 3 different rats (A)--(C). Expected product sizes for rat type II *IL18r1* and *Actb* transcripts were 463 bp and 649 bp, respectively.
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Click here for additional data file.
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###### Alignment of nucleotide *IL18R1* (A) and protein IL-18R*α* (B) sequences from multiple species

Alignments show conserved reading frames across species, the site of insertion of an unspliced intron in type II *IL18R1* nucleotide sequences (arrow and dotted line in (A)), and the corresponding point in protein sequences (arrow and dotted lines in (B)) at which the more C-terminal amino acids shown would be replaced by those encoded by the unspliced intron (shown in [Fig. 5](#fig-5){ref-type="fig"}).
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Click here for additional data file.
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###### Species with *H. Sapiens* IL18r1 homologues in Ensembl

Note that the two identified Guinea Pig sequences differ in their 3rd Ig domain (site of IL-18 binding) and are referred to by shorthand identifiers in the text and figures: \* shorthand identifier Guinea Pig 22527 (for Gene ID: [ENSCPOG00000022527](ENSCPOG00000022527)), † shorthand identifier Guinea Pig 14114 (Gene ID: [ENSCPOG00000014114](ENSCPOG00000014114)).

###### 

Click here for additional data file.
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